{"id":46004,"date":"2022-07-11T12:02:29","date_gmt":"2022-07-11T10:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/"},"modified":"2022-07-11T12:02:29","modified_gmt":"2022-07-11T10:02:29","slug":"community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/","title":{"rendered":"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5523887\/community-acquired-bacterial-pneumonia-cabp?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=9m2lvw&amp;utm_campaign=1723856+-+Community-Acquired+Bacterial+Pneumonia+(CABP)+Market+and+Epidemiology+Report+2022&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Community-Acquired Bacterial Pneumonia (CABP) &#8211; Market Insight, Epidemiology and Market Forecast -2032&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/21\/logo.jpg\"><\/a><\/p>\n<p>\n<strong>Key Findings<\/strong>\n<\/p>\n<p>\nThe disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.\n<\/p>\n<p>\n<strong>Community-Acquired Bacterial Pneumonia (CABP) Drug Chapters<\/strong>\n<\/p>\n<p>\nDrug chapter segment of the Community-Acquired Bacterial Pneumonia (CABP) report encloses the detailed analysis of Community-Acquired Bacterial Pneumonia (CABP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Community-Acquired Bacterial Pneumonia (CABP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.\n<\/p>\n<p>\n<strong>Community-Acquired Bacterial Pneumonia (CABP) Drugs Uptake<\/strong>\n<\/p>\n<p>\nThis section focusses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia (CABP) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Community-Acquired Bacterial Pneumonia (CABP) market uptake by drugs; patient uptake by therapies; and sales of each drug.\n<\/p>\n<p>\nThis helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.\n<\/p>\n<p>\n<strong>Community-Acquired Bacterial Pneumonia (CABP) Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Community-Acquired Bacterial Pneumonia (CABP) key players involved in developing targeted therapeutics.\n<\/p>\n<p>\n<strong>Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Community-Acquired Bacterial Pneumonia (CABP) emerging therapies.\n<\/p>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<ul>\n<li>\nIn the coming years, Community-Acquired Bacterial Pneumonia (CABP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market\n<\/li>\n<li>\nThe companies and academics are working to assess challenges and seek opportunities that could influence Community-Acquired Bacterial Pneumonia (CABP) R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition\n<\/li>\n<li>\nMajor players are involved in developing therapies for Community-Acquired Bacterial Pneumonia (CABP). Launch of emerging therapies will significantly impact the Community-Acquired Bacterial Pneumonia (CABP) market\n<\/li>\n<li>\nA better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Community-Acquired Bacterial Pneumonia (CABP)\n<\/li>\n<li>\nOur in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities\n<\/li>\n<\/ul>\n<p>\n<strong>Community-Acquired Bacterial Pneumonia (CABP) Report Insights<\/strong>\n<\/p>\n<ul>\n<li>\nPatient Population\n<\/li>\n<li>\nTherapeutic Approaches\n<\/li>\n<li>\nCommunity-Acquired Bacterial Pneumonia (CABP) Pipeline Analysis\n<\/li>\n<li>\nCommunity-Acquired Bacterial Pneumonia (CABP) Market Size and Trends\n<\/li>\n<li>\nMarket Opportunities\n<\/li>\n<li>\nImpact of upcoming Therapies\n<\/li>\n<\/ul>\n<p>\n<strong>Community-Acquired Bacterial Pneumonia (CABP) Report Assessment<\/strong>\n<\/p>\n<p>\nCurrent Treatment Practices\n<\/p>\n<ul>\n<li>\nUnmet Needs\n<\/li>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nMarket Attractiveness\n<\/li>\n<li>\nMarket Drivers and Barriers\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Key Insights<\/strong>\n<\/p>\n<p>\n<strong>2. Report Introduction<\/strong>\n<\/p>\n<p>\n<strong>3. Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance<\/strong>\n<\/p>\n<p>\n3.1. Market Share (%) Distribution Community-Acquired Bacterial Pneumonia (CABP) in 2019\n<\/p>\n<p>\n3.2. Market Share (%) Distribution of Community-Acquired Bacterial Pneumonia (CABP) in 2032\n<\/p>\n<p>\n<strong>4. Executive Summary of Community-Acquired Bacterial Pneumonia (CABP)<\/strong>\n<\/p>\n<p>\n<strong>5. Disease Background and Overview<\/strong>\n<\/p>\n<p>\n<strong>6. Treatment and Management<\/strong>\n<\/p>\n<p>\n6.1. Antibiotic therapy\n<\/p>\n<p>\n6.2. Diuretics\n<\/p>\n<p>\n6.3. Corticosteroids\n<\/p>\n<p>\n6.4. Later management\n<\/p>\n<p>\n6.5. Diagnostic and Treatment Guidelines\n<\/p>\n<p>\n6.5.1. The American Thoracic Society and the Infectious Diseases Society of America\n<\/p>\n<p>\n6.5.2. NICE\n<\/p>\n<p>\n<strong>7. Epidemiology and Patient Population<\/strong>\n<\/p>\n<p>\n<strong>8. Patient Journey 1<\/strong>\n<\/p>\n<p>\n<strong>9. Patient Journey 2<\/strong>\n<\/p>\n<p>\n<strong>10. Marketed Therapies<\/strong>\n<\/p>\n<p>\n10.1. Lefamulin (Xenleta): Nabriva Therapeutics\n<\/p>\n<p>\n10.2. Delafloxacin &#8211; Melinta Therapeutics\/Wakunaga Pharmaceutical\n<\/p>\n<p>\n10.3. Ceftaroline fosamil (Teflaro): Forest Pharmaceuticals\n<\/p>\n<p>\n10.4. Linezolid (Zyvox): Pfizer\n<\/p>\n<p>\n10.5. Omadacycline (NUZYRA): Paratek Pharmaceuticals\n<\/p>\n<p>\n10.6. Telavancin (Vibativ): Cumberland Pharmaceuticals Inc.\/Theravance Biopharma\n<\/p>\n<p>\n10.7. Ceftolozane\/Tazobactam (Zerbaxa): Merck Sharp &amp; Dohme Inc.\/Cubist Pharmaceuticals LLC\n<\/p>\n<p>\n10.8. Imipenem\/Cilastatin\/Relebactam (RecarbrioT): Merck Sharp and Dohme\n<\/p>\n<p>\n10.9. Cefiderocol ( Fetroja): Shionogi Inc.\n<\/p>\n<p>\n10.10. Ceftazidime\/Avibactam (Avycaz): Allergan\/Pfizer\n<\/p>\n<p>\n<strong>11. Emerging Drugs<\/strong>\n<\/p>\n<p>\n11.1. CAL02: Eagle Pharmaceutical Inc\/Combioxin SA\n<\/p>\n<p>\n11.2. Cx611: Takeda\/TiGenix\n<\/p>\n<p>\n<strong>12. Other Therapies: Generics<\/strong>\n<\/p>\n<p>\n12.1. Amoxicillin\n<\/p>\n<p>\n12.2. Azithromycin\n<\/p>\n<p>\n12.3. Clarithromycin\n<\/p>\n<p>\n12.4. Doxycycline\n<\/p>\n<p>\n12.5. Moxifloxacin\n<\/p>\n<p>\n12.6. Vaccine\n<\/p>\n<p>\n12.6.1. Prevnar 13\n<\/p>\n<p>\n12.6.2. Vaxneuvance\n<\/p>\n<p>\n<strong>13. Community-Acquired Bacterial Pneumonia: 7 Major Market Analysis<\/strong>\n<\/p>\n<p>\n<strong>14. Market Outlook<\/strong>\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nNabriva Therapeutics\n<\/li>\n<li>\nMelinta Therapeutics\n<\/li>\n<li>\nWakunaga Pharmaceutical\n<\/li>\n<li>\nForest Pharmaceuticals\n<\/li>\n<li>\nPfizer\n<\/li>\n<li>\nParatek Pharmaceuticals\n<\/li>\n<li>\nCumberland Pharmaceuticals Inc.\n<\/li>\n<li>\nTheravance Biopharma\n<\/li>\n<li>\nMerck Sharp &amp; Dohme Inc.\n<\/li>\n<li>\nCubist Pharmaceuticals LLC\n<\/li>\n<li>\nShionogi Inc.\n<\/li>\n<li>\nAllergan\n<\/li>\n<li>\nEagle Pharmaceutical Inc\n<\/li>\n<li>\nCombioxin SA\n<\/li>\n<li>\nTakeda\n<\/li>\n<li>\nTiGenix\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5523887\/community-acquired-bacterial-pneumonia-cabp?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=9m2lvw&amp;utm_campaign=1723856+-+Community-Acquired+Bacterial+Pneumonia+(CABP)+Market+and+Epidemiology+Report+2022&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/vtv4k7<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x70;&#114;e&#x73;&#x73;&#64;r&#x65;&#115;e&#x61;&#x72;&#99;h&#x61;&#x6e;&#100;&#x6d;&#x61;&#114;k&#x65;&#x74;&#115;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;r&#x65;&#115;&#x73;&#64;&#x72;&#x65;s&#x65;&#97;&#x72;&#99;&#x68;&#97;n&#x64;&#109;&#x61;&#114;&#x6b;&#101;t&#x73;&#46;&#x63;&#111;&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Community-Acquired Bacterial Pneumonia (CABP) &#8211; Market Insight, Epidemiology and Market Forecast -2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Key Findings The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46004","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Community-Acquired Bacterial Pneumonia (CABP) &#8211; Market Insight, Epidemiology and Market Forecast -2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Key Findings The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-11T10:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-07-11T10:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/\"},\"wordCount\":824,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005402\\\/en\\\/1509217\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/\",\"name\":\"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005402\\\/en\\\/1509217\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-07-11T10:02:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005402\\\/en\\\/1509217\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220711005402\\\/en\\\/1509217\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Community-Acquired Bacterial Pneumonia (CABP) &#8211; Market Insight, Epidemiology and Market Forecast -2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Key Findings The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-11T10:02:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 &#8211; ResearchAndMarkets.com","datePublished":"2022-07-11T10:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/"},"wordCount":824,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/","name":"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/21\/logo.jpg","datePublished":"2022-07-11T10:02:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220711005402\/en\/1509217\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/community-acquired-bacterial-pneumonia-cabp-market-and-epidemiology-report-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46004"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46004\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}